Literature DB >> 35113345

Alternative Routes of Administration of Clozapine.

Siobhan Gee1, David Taylor2,3.   

Abstract

Clozapine is the only antipsychotic with proven effectiveness in treatment-resistant schizophrenia. It is usually administered using commercially available oral tablets, but not all patients are willing or able to take medicines in this way. Orodispersible clozapine tablets are available from several manufacturers and may be useful where swallowing solid dosage forms is difficult, or as an aid to observe compliance. Liquid formulations of clozapine can be prepared extemporaneously or purchased commercially, but most preparations are suspensions (clozapine is poorly soluble) and patients may find them unpalatable. The administration of clozapine (suspension or crushed tablets) via enteral feeding tubes (predominantly nasogastric) has been reported both in medically unwell patients and in patients refusing clozapine. Enteral administration is likely to be superseded by intramuscular clozapine, which has recently been re-introduced and is being widely used in some countries. Successful use of this formulation in enforced treatment strategies has been described by several authors with good long-term outcomes when switched to oral treatment. Intramuscular clozapine has also been used in physically ill patients who are unable to take any form of enteral medication. Other methods of delivery (transdermal, nasal) are not yet commercially available, but offer promise of further treatment options for this group of seriously ill patients.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35113345     DOI: 10.1007/s40263-022-00900-w

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  36 in total

1.  A historical perspective of clozapine.

Authors:  H Hippius
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

2.  Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia.

Authors:  C Guitton; M Abbar; J M Kinowski; P Chabrand; F Bressolle
Journal:  J Clin Psychopharmacol       Date:  1998-12       Impact factor: 3.153

3.  Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

Authors:  M G Choc; F Hsuan; G Honigfeld; W T Robinson; L Ereshefsky; M L Crismon; S R Saklad; J Hirschowitz; R Wagner
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

4.  Multiple-dose pharmacokinetics of clozapine in patients.

Authors:  M G Choc; R G Lehr; F Hsuan; G Honigfeld; H T Smith; R Borison; J Volavka
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

5.  Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.

Authors:  Y F Cheng; T Lundberg; U Bondesson; L Lindström; J Gabrielsson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Biotransformation of clozapine in humans.

Authors:  J G Dain; J Nicoletti; F Ballard
Journal:  Drug Metab Dispos       Date:  1997-05       Impact factor: 3.922

Review 7.  An overview of the mechanism of action of clozapine.

Authors:  H Y Meltzer
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

8.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 9.  Pharmacokinetics and pharmacodynamics of clozapine.

Authors:  M W Jann; S R Grimsley; E C Gray; W H Chang
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

10.  Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia.

Authors:  Grant McQueen; Kyra-Verena Sendt; Amy Gillespie; Alessia Avila; John Lally; Kalliopi Vallianatou; Nynn Chang; Diogo Ferreira; Faith Borgan; Oliver D Howes; Gareth J Barker; David J Lythgoe; James M Stone; Philip McGuire; James H MacCabe; Alice Egerton
Journal:  Schizophr Bull       Date:  2021-04-29       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.